Stephanie Kim Cheok

Stephanie Kim Cheok

Auto-generated profile, based on publicly available information

Stephanie Kim Cheok

Department of Neurosurgery, Medical College of Wisconsin, Milwaukee, Wisconsin, USA

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2024 in Journal of Neurosurgery
Verified
Journal Article
Closed access
PDF file
SCStephanie K. Cheok
Stephanie K. Cheok
JCJohn D. Carmichael
John D. Carmichael
GZGabriel Zada
Gabriel Zada
This review aimed to highlight the history, diagnostic criteria, preoperative prognostic factors, surgical management, and multimodal adjuvant therapies recommended to provide a comprehensive and multifaceted understanding of and clinical approach to treating growth hormone–secreting pituitary adenomas (GHPAs) in patients with acromegaly. The authors collated and reviewed published studies, many written by skull base neurosurgeons, endocrinologists, and radiation oncologists with expertise in pituitary adenoma management, to produce a practical and contemporary update pertaining to the optimal management of acromegaly for neurosurgeons. Acromegaly is a debilitating disease for which surgery can be curative in more than two-thirds of patients. Recent rates of hormonal remission by the authors’ group and others following the resection of GHPAs are on the order of 70%–80%, and these increase to more than 85% with the addition of medical therapy in a minority of patients who do not achieve remission with surgery alone. Most tumors are accessible via a direct endoscopic endonasal transsphenoidal approach, which can be augmented with a variety of extended approaches to gain access to suprasellar, clival, and parasellar compartments as needed. Preoperative growth hormone levels, cavernous sinus invasion, and pituitary adenoma consistency are important factors in determining the extent of resection. In most patients with residual or recurrent disease, medical therapy (e.g., somatostatin analogs and dopamine agonists) can be used to help achieve hormonal remission. Repeat surgery can be safely performed in most cases if needed, whereas stereotactic radiosurgery is usually reserved for medically resistant tumors in surgically inaccessible compartments. The neurosurgeon has a primary and often definitive role in the management of acromegaly. The involvement of an integrated and multidisciplinary team consisting of experts from neurosurgery, otolaryngology, endocrinology, and radiation oncology optimizes the chances for a biochemical cure, even in large and aggressive GHPAs.

1 August 2023 in Neurosurgical Focus
Verified
Journal Article
Closed access
PDF file
SCStephanie K. Cheok
Stephanie K. Cheok
CYCheng Yu
Cheng Yu
JFJeffrey J. Feng
Jeffrey J. Feng
RBRobert G. Briggs
Robert G. Briggs
FCFrances Chow
Frances Chow
GZGabriel Zada
Gabriel Zada
OBJECTIVE: Stereotactic radiosurgery (SRS) for operative brain metastasis (BrM) is usually administered 1 to 6 weeks after resection. Preoperative versus postoperative timing of SRS delivery related to surgery remains a critical question, as a pattern of failure is the development of leptomeningeal disease (LMD) in as many as 35% of patients who undergo postoperative SRS or the occurrence of radiation necrosis. As they await level I clinical data from ongoing trials, the authors aimed to bridge the gap by comparing postoperative with simulated preoperative single-fraction SRS dosimetry plans for patients with surgically resected BrM. METHODS: The authors queried their institutional database to retrospectively identify patients who underwent postoperative Gamma Knife SRS (GKSRS) after resection of BrM between January 2014 and January 2021. Exclusion criteria were prior radiation delivered to the lesion, age < 18 years, and prior diagnosis of LMD. Once identified, a simulated preoperative SRS plan was designed to treat the unresected BrM and compared with the standard postoperative treatment delivered to the resection cavity per Radiation Therapy Oncology Group (RTOG) 90–05 guidelines. Numerous comparisons between preoperative and postoperative GKSRS treatment parameters were then made using paired statistical analyses. RESULTS: The authors’ cohort included 45 patients with a median age of 59 years who were treated with GKSRS after resection of a BrM. Primary cancer origins included colorectal cancer (27%), non–small cell lung cancer (22%), breast cancer (11%), melanoma (11%), and others (29%). The mean tumor and cavity volumes were 15.06 cm 3 and 12.61 cm 3 , respectively. In a paired comparison, there was no significant difference in the planned treatment volumes between the two groups. When the authors compared the volume of surrounding brain that received 12 Gy or more (V12Gy), an important predictor of radiation necrosis, 64% of patient plans in the postoperative SRS group (29/45, p = 0.008) recorded greater V12 volumes. Preoperative plans were more conformal (p < 0.001) and exhibited sharper dose drop-off at the lesion margins (p = 0.0018) when compared with postoperative plans. CONCLUSIONS: Comparison of simulated preoperative and delivered postoperative SRS plans administered to the BrM or resection cavity suggested that preoperative SRS allows for more highly conformal lesional coverage and sharper dose drop-off compared with postoperative plans. Furthermore, V12Gy was lower in the presurgical GKSRS plans, which may account for the decreased incidence of radiation necrosis seen in prior retrospective studies.

28 November 2024 in Journal of Neuro-Oncology
Verified
Journal Article
Closed access
PDF file
SCStephanie Kim Cheok
Stephanie Kim Cheok
STSamon Tavakoli-Sabour
Samon Tavakoli-Sabour
RBRyan T. Beck
Ryan T. Beck
NZNathan Zwagerman
Nathan Zwagerman
AIAdriana Ioachimescu
Adriana Ioachimescu

14 November 2023 in World Neurosurgery
Verified
Journal Article
Closed access
IBIlaria Bove
Ilaria Bove
SCStephanie K. Cheok
Stephanie K. Cheok
JFJeffrey J. Feng
Jeffrey J. Feng
RBRobert G. Briggs
Robert G. Briggs
JRJacob Ruzevick
Jacob Ruzevick
GZGabriel Zada
Gabriel Zada

6 August 2025 in Clinical Neurology and Neurosurgery
Verified
Journal Article
Closed access
HMHailey Mattheisen
Hailey Mattheisen
APAbigail Peterson
Abigail Peterson
AMAbdullah A. Memon
Abdullah A. Memon
EME. Kelly S. Mrachek
E. Kelly S. Mrachek
STSamon Tavakoli
Samon Tavakoli
SCStephanie Cheok
Stephanie Cheok

19 December 2022 in Operative Neurosurgery
Verified
Journal Article
Closed access
SCStephanie Kim Cheok
Stephanie Kim Cheok
GZGabriel Zada
Gabriel Zada